输血依赖型β地中海贫血患儿的双重口服铁螯合剂 (DOIC):真实世界的疗效数据

IF 0.9 4区 医学
Amitoj Singh Chadha, Abaan Ul Haq Khazi Mohammad, Naveen Kanth Dhãmi Nadakuditi, Surbhi Agrawal, Kenson Sam Alex, Namratha S. Naik, John Michael Raj, Anand Prakash
{"title":"输血依赖型β地中海贫血患儿的双重口服铁螯合剂 (DOIC):真实世界的疗效数据","authors":"Amitoj Singh Chadha, Abaan Ul Haq Khazi Mohammad, Naveen Kanth Dhãmi Nadakuditi, Surbhi Agrawal, Kenson Sam Alex, Namratha S. Naik, John Michael Raj, Anand Prakash","doi":"10.1007/s12288-024-01804-z","DOIUrl":null,"url":null,"abstract":"<p>Combination chelation with deferiprone (DFP) and deferasirox (DFX) is one of the treatment modalities for iron overload in children with Transfusion-dependent Thalassemia (TDT). We report our experience with dual oral iron chelation. Retrospective chart review was conducted on all children started on Dual Oral Iron Chelation (DOIC) from 2015 to 2022. Children with TDT requiring DOIC were included in the study. Forty-five children required DOIC. The mean SF before DOIC initiation was 2929 ng/dl (SD 1465.07). The mean ferritin following DOIC was 1962.10 ng/dl (SD 1165.83) at 30 months. Mean duration on DOIC was 44.6 months (IQR 60–30). With DOIC, 82.22% children had a fall in ferritin to &lt; 2000 ng/dl and in 60% of them had fall to &lt; 1000 ng/dL. Dual Oral Iron Chelation (DOIC) is efficacious in reducing ferritin in iron-overloaded patients. Higher ferritin values (&gt; 2500 ng/dL) drop rapidly in the first 12–24 months. DOIC was well-tolerated with no severe adverse effects.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"22 1","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dual Oral Iron Chelation (DOIC) in Children with Transfusion-Dependent Beta Thalassemia: Real-World Efficacy Data\",\"authors\":\"Amitoj Singh Chadha, Abaan Ul Haq Khazi Mohammad, Naveen Kanth Dhãmi Nadakuditi, Surbhi Agrawal, Kenson Sam Alex, Namratha S. Naik, John Michael Raj, Anand Prakash\",\"doi\":\"10.1007/s12288-024-01804-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Combination chelation with deferiprone (DFP) and deferasirox (DFX) is one of the treatment modalities for iron overload in children with Transfusion-dependent Thalassemia (TDT). We report our experience with dual oral iron chelation. Retrospective chart review was conducted on all children started on Dual Oral Iron Chelation (DOIC) from 2015 to 2022. Children with TDT requiring DOIC were included in the study. Forty-five children required DOIC. The mean SF before DOIC initiation was 2929 ng/dl (SD 1465.07). The mean ferritin following DOIC was 1962.10 ng/dl (SD 1165.83) at 30 months. Mean duration on DOIC was 44.6 months (IQR 60–30). With DOIC, 82.22% children had a fall in ferritin to &lt; 2000 ng/dl and in 60% of them had fall to &lt; 1000 ng/dL. Dual Oral Iron Chelation (DOIC) is efficacious in reducing ferritin in iron-overloaded patients. Higher ferritin values (&gt; 2500 ng/dL) drop rapidly in the first 12–24 months. DOIC was well-tolerated with no severe adverse effects.</p>\",\"PeriodicalId\":13314,\"journal\":{\"name\":\"Indian Journal of Hematology and Blood Transfusion\",\"volume\":\"22 1\",\"pages\":\"\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Hematology and Blood Transfusion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12288-024-01804-z\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Hematology and Blood Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12288-024-01804-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

去铁酮(DFP)和去铁胺(DFX)联合螯合是治疗输血依赖型地中海贫血(TDT)患儿铁过载的方法之一。我们报告了双重口服铁螯合剂的经验。我们对2015年至2022年期间开始使用双口服铁螯合剂(DOIC)的所有儿童进行了回顾性病历审查。需要接受 DOIC 的 TDT 患儿被纳入研究范围。45名儿童需要接受DOIC治疗。开始使用 DOIC 前的平均 SF 为 2929 ng/dl(SD 1465.07)。30 个月时,DOIC 后的铁蛋白平均值为 1962.10 ng/dl (SD 1165.83)。服用 DOIC 的平均时间为 44.6 个月(IQR 60-30)。服用 DOIC 后,82.22% 的儿童铁蛋白降至 2000 ng/dl,其中 60% 的儿童降至 1000 ng/dL。双重口服铁螯合剂(DOIC)能有效降低铁负荷过重患者的铁蛋白。较高的铁蛋白值(2500 ng/dL)会在最初的 12-24 个月内迅速下降。DOIC 耐受性良好,无严重不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Dual Oral Iron Chelation (DOIC) in Children with Transfusion-Dependent Beta Thalassemia: Real-World Efficacy Data

Dual Oral Iron Chelation (DOIC) in Children with Transfusion-Dependent Beta Thalassemia: Real-World Efficacy Data

Combination chelation with deferiprone (DFP) and deferasirox (DFX) is one of the treatment modalities for iron overload in children with Transfusion-dependent Thalassemia (TDT). We report our experience with dual oral iron chelation. Retrospective chart review was conducted on all children started on Dual Oral Iron Chelation (DOIC) from 2015 to 2022. Children with TDT requiring DOIC were included in the study. Forty-five children required DOIC. The mean SF before DOIC initiation was 2929 ng/dl (SD 1465.07). The mean ferritin following DOIC was 1962.10 ng/dl (SD 1165.83) at 30 months. Mean duration on DOIC was 44.6 months (IQR 60–30). With DOIC, 82.22% children had a fall in ferritin to < 2000 ng/dl and in 60% of them had fall to < 1000 ng/dL. Dual Oral Iron Chelation (DOIC) is efficacious in reducing ferritin in iron-overloaded patients. Higher ferritin values (> 2500 ng/dL) drop rapidly in the first 12–24 months. DOIC was well-tolerated with no severe adverse effects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
82
期刊介绍: Indian Journal of Hematology and Blood Transfusion is a medium for propagating and exchanging ideas within the medical community. It publishes peer-reviewed articles on a variety of aspects of clinical hematology, laboratory hematology and hemato-oncology. The journal exists to encourage scientific investigation in the study of blood in health and in disease; to promote and foster the exchange and diffusion of knowledge relating to blood and blood-forming tissues; and to provide a forum for discussion of hematological subjects on a national scale. The Journal is the official publication of The Indian Society of Hematology & Blood Transfusion.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信